Spectral CT Protocol Optimization for Atherosclerotic Plaque CharacterizatION
Launched by IRCCS SYNLAB SDN · Mar 14, 2025
Trial Information
Current as of April 26, 2025
Active, not recruiting
Keywords
ClinConnect Summary
The SCORPION study is researching how to better understand a condition called atherosclerotic disease, which affects blood vessels and can lead to serious heart problems. This study aims to improve a specific type of imaging called dual-energy CT (DECT) and photon-counting CT (PCCT) to more accurately identify different types of plaque in the arteries. By refining these imaging techniques, the hope is to provide doctors with better tools for assessing patients' heart disease risks and improving their care.
To participate in the study, individuals must be over 60 years old and have had DECT imaging for heart-related issues, specifically if they have significant narrowing (more than 75%) of their coronary or carotid arteries. The study involves analyzing scans from patients to create a standardized method for plaque assessment. Participants can expect their previous imaging data to be reviewed and, if they qualify, to possibly undergo additional scans using advanced technology. Overall, this research aims to enhance how heart diseases are diagnosed and managed, ultimately leading to better outcomes for patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who have undergone DECT for cardiovascular imaging (coronary and/or carotid)
- • Patients with critical stenosis (\>75% diameter, coronary or carotid artery) aged \> 60aa
- Exclusion Criteria:
- • Patients negative for critical stenosis (\<75% diameter) and/or imaging artefacts (e.g. due to movement, swallowing, or arrhythmias).
- • Patients under 60 years of age
- • Patients allergic to iodinated contrast medium (prospective phase)
- • Patients with chronic renal insufficiency (prospective phase)
About Irccs Synlab Sdn
IRCCS Synlab SDN is a leading clinical research organization dedicated to advancing medical science through innovative research and development. As a recognized Institute for Health Research, Synlab SDN specializes in conducting high-quality clinical trials across various therapeutic areas, aiming to improve patient outcomes and contribute to the global body of medical knowledge. With a commitment to ethical standards and regulatory compliance, Synlab SDN collaborates with healthcare professionals and industry partners to ensure the integrity and efficacy of its research initiatives, ultimately striving to bring new treatments to market swiftly and safely.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Naples, , Italy
Patients applied
Trial Officials
Carlo Cavaliere, MD
Principal Investigator
carlo.cavaliere@synlab.it
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported